| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,767 |
4,552 |
$470K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,135 |
5,915 |
$343K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
3,456 |
3,329 |
$157K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,272 |
1,271 |
$106K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,274 |
1,274 |
$105K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,848 |
1,809 |
$94K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,019 |
1,009 |
$79K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
757 |
757 |
$69K |
| 90461 |
|
1,451 |
1,446 |
$49K |
| S0302 |
Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) |
5,185 |
5,179 |
$48K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
531 |
526 |
$43K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
3,599 |
3,587 |
$38K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
924 |
906 |
$29K |
| 92552 |
|
670 |
669 |
$15K |
| 96127 |
|
1,320 |
1,320 |
$14K |
| 99173 |
|
599 |
598 |
$13K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
831 |
821 |
$10K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
42 |
42 |
$8K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
72 |
72 |
$7K |
| 87634 |
|
92 |
92 |
$6K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
244 |
244 |
$5K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
271 |
268 |
$5K |
| 87081 |
|
661 |
654 |
$4K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
172 |
169 |
$3K |
| 99051 |
|
122 |
120 |
$2K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
60 |
60 |
$2K |
| 0124A |
|
34 |
34 |
$2K |
| 99050 |
|
79 |
79 |
$1K |
| 85018 |
|
630 |
629 |
$1K |
| 0071A |
|
30 |
30 |
$1K |
| 99188 |
|
36 |
36 |
$936.00 |
| 0001A |
|
14 |
14 |
$642.32 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
28 |
28 |
$342.44 |
| 90688 |
|
12 |
12 |
$132.00 |
| 81003 |
|
51 |
48 |
$100.98 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
13 |
13 |
$3.80 |